Besides establishing that CD44 is required for PRG4 to enhance the anti-proliferative activity of regorafenib, we also determined that the expression of CD44 is restricted to HCC cell lines previously characterized as being more aggressive, according to Coulouarn et al. [43]. The gene discussed is PRG4; the disease is hepatocellular carcinoma.